<?xml version="1.0" encoding="UTF-8"?>
<ref id="B43-vaccines-08-00224">
 <label>43.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Decroly</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Imbert</surname>
    <given-names>I.</given-names>
   </name>
   <name>
    <surname>Coutard</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Bouvet</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Selisko</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Alvarez</surname>
    <given-names>K.</given-names>
   </name>
   <name>
    <surname>Gorbalenya</surname>
    <given-names>A.E.</given-names>
   </name>
   <name>
    <surname>Snijder</surname>
    <given-names>E.J.</given-names>
   </name>
   <name>
    <surname>Canard</surname>
    <given-names>B.</given-names>
   </name>
  </person-group>
  <article-title>Coronavirus nonstructural protein 16 is a cap-0 binding enzyme possessing (nucleoside-2â€™O)-methyltransferase activity</article-title>
  <source>J. Virol.</source>
  <year>2008</year>
  <volume>82</volume>
  <fpage>8071</fpage>
  <lpage>8084</lpage>
  <pub-id pub-id-type="doi">10.1128/JVI.00407-08</pub-id>
  <?supplied-pmid 18417574?>
  <pub-id pub-id-type="pmid">18417574</pub-id>
 </element-citation>
</ref>
